Fasudil trial phase 1 study(FAS1)

Fasudil trial phase 1 study (FAS1)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041210145

Enrollment

Registered

2022-02-14

Start date

2022-11-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Interventions

Cohort 1: fasudil hydrochloride 15mg once orally after breakfast Cohort 2: fasudil hydrochloride 30mg once orally after breakfast

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) healthy volunteers 2) age from 20 to 60, weight from 50kg and more, body mass index from 15 to 30 kg/m2 3) perfomance status is 0 4) persons with written informed consent 5) volunteers response to Student bulletin board or request by volunteer introduction companies

Exclusion criteria

Exclusion criteria: 1) persons with allergy against fasudil or nitrate 2) peasons with allergy for fasudil, pregnancy or breastfeeding 3) persons with diabetes mellitus, renal dysfunction, liver dysfunction, smoking, obesity, allergic disease 4) persons who study groups consider inappropriate for this study

Design outcomes

Primary

Measure	Time frame
To measure the blood concentration of M3 (active metabolite of fasudil) from 0 and to 6 hours after taking fasudil	—

Secondary

Measure	Time frame
Early allergic reaction, adverse effect such as hypotension	—

Contacts

Public ContactRyuji Okamoto

Mie University Hospital

ryuji@clin.medic.mie-u.ac.jp+81-59-231-5015

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026